Regulation of lipid metabolism by obeticholic acid in hyperlipidemic hamsters

Journal of Lipid Research

Volumn 58, Issue 2, 2017, Pages 350-363

  Dong, Bin ^a   Young, Mark ^b   Liu, Xueqing ^b   Singh, Amar Bahadur ^a   Liu, Jingwen ^a  

^a VA PALO ALTO HEALTH CARE SYSTEM   (United States)

^b INTERCEPT PHARMACEUTICALS   (United States)

Author keywords

Farnesoid X receptor; Hepatocyte nuclear factor 4 jlr; High density lipoprotein cholesterol; Low density lipoprotein receptor; Scavenger receptor class B type I; Sterol regulatory elementbinding protein 2

Indexed keywords

ABC TRANSPORTER A1; ALANINE AMINOTRANSFERASE; APOLIPOPROTEIN A1; BILIRUBIN; CHOLESTEROL; COLLAGEN TYPE 1; HEPATOCYTE NUCLEAR FACTOR 4ALPHA; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LIPID; LOW DENSITY LIPOPROTEIN CHOLESTEROL; MESSENGER RNA; OBETICHOLIC ACID; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR ALPHA; PROPROTEIN CONVERTASE 9; SCAVENGER RECEPTOR BI; TRIACYLGLYCEROL; TUMOR NECROSIS FACTOR; VERY LOW DENSITY LIPOPROTEIN CHOLESTEROL; CD36 ANTIGEN; CHENODEOXYCHOLIC ACID;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CHOLESTEROL BLOOD LEVEL; CHOLESTEROL TRANSPORT; CONTROLLED STUDY; CORRELATION ANALYSIS; DRUG DOSE COMPARISON; FECES LEVEL; HAMSTER; HYPERLIPIDEMIA; LIPID BLOOD LEVEL; LIPID METABOLISM; LIVER LEVEL; MALE; NONHUMAN; PROTEIN EXPRESSION; RECEPTOR UPREGULATION; TIME; TREATMENT DURATION; TREATMENT OUTCOME; ANALOGS AND DERIVATIVES; ANIMAL; BIOSYNTHESIS; DRUG EFFECTS; GENE EXPRESSION REGULATION; GENETICS; HUMAN; LIVER; LIVER CELL; METABOLISM; PATHOLOGY; TRANSCRIPTION INITIATION;

ANIMALS; ANTIGENS, CD36; CHENODEOXYCHOLIC ACID; CHOLESTEROL, HDL; CRICETINAE; GENE EXPRESSION REGULATION; HEPATOCYTES; HUMANS; HYPERLIPIDEMIAS; LIPID METABOLISM; LIVER; RNA, MESSENGER; TRANSCRIPTIONAL ACTIVATION;

EID: 85011264042     PISSN: 00222275     EISSN: 15397262     Source Type: Journal    
DOI: 10.1194/jlr.M070888     Document Type: Article

References (51)

1. Calkin, A. C., and P. Tontonoz. 2012. Transcriptional integration of metabolism by the nuclear sterol-activated receptors LXR and FXR. Nat. Rev. Mol. Cell Biol. 13: 213-224.
2. Thomas, A. M., S. N. Hart, B. Kong, J. Fang, X. B. Zhong, and G. L. Guo. 2010. Genome-wide tissue-specific farnesoid X receptor binding in mouse liver and intestine. Hepatology. 51: 1410-1419.
3. Zhan, L., H. X. Liu, Y. Fang, B. Kong, Y. He, X. B. Zhong, J. Fang, Y. J. Wan, and G. L. Guo. 2014. Genome-wide binding and transcriptome analysis of human farnesoid X receptor in primary human hepatocytes. PLoS One. 9: e105930.
4. de Aguiar Vallim, T. Q., E. J. Tarling, H. Ahn, L. R. Hagey, C. E. Romanoski, R. G. Lee, M. J. Graham, H. Motohashi, M. Yamamoto, and P. A. Edwards. 2015. MAFG is a transcriptional repressor of bile acid synthesis and metabolism. Cell Metab. 21: 298-310.
5. Rigotti, A., B. Trigatti, J. Babitt, M. Penman, S. Xu, and M. Krieger. 1997. Scavenger receptor BI-a cell surface receptor for high density lipoprotein. Curr. Opin. Lipidol. 8: 181-188.
6. Rigotti, A., B. L. Trigatti, M. Penman, H. Rayburn, J. Herz, and M. Krieger. 1997. A targeted mutation in the murine gene encoding the high density lipoprotein (HDL) receptor scavenger receptor class B type I reveals its key role in HDL metabolism 8. Proc. Natl. Acad. Sci. USA. 94: 12610-12615.
7. Shen, W. J., J. Hu, Z. Hu, F. B. Kraemer, and S. Azhar. 2014. Scavenger receptor class B type I (SR-BI): a versatile receptor with multiple functions and actions. Metabolism. 63: 875-886.
8. Brodeur, M. R., V. Luangrath, G. Bourret, L. Falstrault, and L. Brissette. 2005. Physiological importance of SR-BI in the in vivo metabolism of human HDL and LDL in male and female mice. J. Lipid Res. 46: 687-696.
9. Zanoni, P., S. A. Khetarpal, D. B. Larach, W. F. Hancock-Cerutti, J. S. Millar, M. Cuchel, S. DerOhannessian, A. Kontush, P. Surendran, D. Saleheen, et al. 2016. Rare variant in scavenger receptor BI raises HDL cholesterol and increases risk of coronary heart disease. Science. 351: 1166-1171.
10. Kozarsky, K. F., M. H. Donahee, J. M. Glick, M. Krieger, and D. J. Rader. 2000. Gene transfer and hepatic overexpression of the HDL receptor SR-BI reduces atherosclerosis in the cholesterol-fed LDL receptor-deficient mouse. Arterioscler. Thromb. Vasc. Biol. 20: 721-727.
11. Kozarsky, K. F., M. H. Donahee, A. Rigotti, S. N. Iqbal, E. R. Edelman, and M. Krieger. 1997. Overexpression of the HDL receptor SR-BI alters plasma HDL and bile cholesterol levels. Nature. 387: 414-417.
12. Van Eck, M., J. Twisk, M. Hoekstra, B. T. Van Rij, C. A. Van der Lans, I. S. Bos, J. K. Kruijt, F. Kuipers, and T. J. Van Berkel. 2003. Differential effects of scavenger receptor BI deficiency on lipid metabolism in cells of the arterial wall and in the liver. J. Biol. Chem. 278: 23699-23705.
13. Fuller, M., O. Dadoo, V. Serkis, D. Abutouk, M. MacDonald, N. Dhingani, J. Macri, S. A. Igdoura, and B. L. Trigatti. 2014. The effects of diet on occlusive coronary artery atherosclerosis and myocardial infarction in scavenger receptor class B, type 1/low-density lipoprotein receptor double knockout mice. Arterioscler. Thromb. Vasc. Biol. 34: 2394-2403.
14. Vergeer, M., S. J. Korporaal, R. Franssen, I. Meurs, R. Out, G. K. Hovingh, M. Hoekstra, J. A. Sierts, G. M. Dallinga-Thie, M. M. Motazacker, et al. 2011. Genetic variant of the scavenger receptor BI in humans. N. Engl. J. Med. 364: 136-145.
15. Brunham, L. R., I. Tietjen, A. E. Bochem, R. R. Singaraja, P. L. Franchini, C. Radomski, M. Mattice, A. Legendre, G. K. Hovingh, J. J. Kastelein, et al. 2011. Novel mutations in scavenger receptor BI associated with high HDL cholesterol in humans. Clin. Genet. 79: 575-581.
16. Adorini, L., M. Pruzanski, and D. Shapiro. 2012. Farnesoid X receptor targeting to treat nonalcoholic steatohepatitis. Drug Discov. Today. 17: 988-997.
17. Neuschwander-Tetri, B. A., R. Loomba, A. J. Sanyal, J. E. Lavine, M. L. Van Natta, M. F. Abdelmalek, N. Chalasani, S. Dasarathy, A. M. Diehl, B. Hameed, et al. 2015. Farnesoid X nuclear receptor ligand obeticholic acid for non-cirrhotic, non-alcoholic steatohepatitis (FLINT): a multicentre, randomised, placebo-controlled trial. Lancet. 385: 956-965.
18. Mudaliar, S., R. R. Henry, A. J. Sanyal, L. Morrow, H. U. Marschall, M. Kipnes, L. Adorini, C. I. Sciacca, P. Clopton, E. Castelloe, et al. 2013. Efficacy and safety of the farnesoid X receptor agonist obeticholic acid in patients with type 2 diabetes and nonalcoholic fatty liver disease. Gastroenterology. 145: 574-582.
19. Pencek, R., T. Marmon, J. D. Roth, A. Liberman, R. Hooshmand- Rad, and M. Young. 2016. Effects of obeticholic acid on lipoprotein metabolism in healthy volunteers. Diabetes Obes. Metab. 18: 936-940.
20. Hirschfield, G. M., A. Mason, V. Luketic, K. Lindor, S. C. Gordon, M. Mayo, K. V. Kowdley, C. Vincent, H. C. Bodhenheimer, A. Pares, et al. 2015. Efficacy of obeticholic acid in patients with primary biliary cirrhosis and inadequate response to ursodeoxycholic acid. Gastroenterology. 148: 751-761.
21. Cipriani, S., A. Mencarelli, G. Palladino, and S. Fiorucci. 2010. FXR activation reverses insulin resistance and lipid abnormalities and protects against liver steatosis in Zucker (fa/fa) obese rats. J. Lipid Res. 51: 771-784.
22. Gardès, C., E. Chaput, A. Staempfli, D. Blum, H. Richter, and G. M. Benson. 2013. Differential regulation of bile acid and cholesterol metabolism by the farnesoid X receptor in Ldlr -/- mice versus hamsters. J. Lipid Res. 54: 1283-1299.
23. Hambruch, E., S. Miyazaki-Anzai, U. Hahn, S. Matysik, A. Boettcher, S. Perovic-Ottstadt, T. Schluter, O. Kinzel, H. D. Krol, U. Deuschle, et al. 2012. Synthetic farnesoid X receptor agonists induce highdensity lipoprotein-mediated transhepatic cholesterol efflux in mice and monkeys and prevent atherosclerosis in cholesteryl ester transfer protein transgenic low-density lipoprotein receptor (-/-) mice. J. Pharmacol. Exp. Ther. 343: 556-567.
24. Gardès, C., D. Blum, K. Bleicher, E. Chaput, M. Ebeling, P. Hartman, C. Handschin, H. Richter, and G. M. Benson. 2011. Studies in mice, hamsters, and rats demonstrate that repression of hepatic apoA-I expression by taurocholic acid in mice is not mediated by the farnesoid- X-receptor. J. Lipid Res. 52: 1188-1199.
25. Dong, B., A. B. Singh, C. F. K. Kan, and J. Liu. 2014. CETP inhibitors downregulate hepatic LDL receptor and PCSK9 expression in vitro and in vivo through a SREBP2 dependent mechanism. Atherosclerosis. 235: 449-462.
26. Dong, B., H. Li, A. B. Singh, A. Cao, and J. Liu. 2015. Inhibition of PCSK9 transcription by berberine involves down-regulation of hepatic HNF1alpha protein expression through the ubiquitin-proteasome degradation pathway. J. Biol. Chem. 290: 4047-4058.
27. Yu, C., F. Wang, M. Kan, C. Jin, R. B. Jones, M. Weinstein, C. X. Deng, and W. L. McKeehan. 2000. Elevated cholesterol metabolism and bile acid synthesis in mice lacking membrane tyrosine kinase receptor FGFR4. J. Biol. Chem. 275: 15482-15489.
28. Cao, A., M. Wu, H. Li, and J. Liu. 2011. Janus kinase activation by cytokine oncostatin M decreases PCSK9 expression in liver cells. J. Lipid Res. 52: 518-530.
29. Li, H., B. Dong, S. W. Park, H. S. Lee, W. Chen, and J. Liu. 2009. Hepatocyte nuclear factor 1alpha plays a critical role in PCSK9 gene transcription and regulation by the natural hypocholesterolemic compound berberine. J. Biol. Chem. 284: 28885-28895.
30. Evans, M. J., P. E. Mahaney, L. Borges-Marcucci, K. Lai, S. Wang, J. A. Krueger, S. J. Gardell, C. Huard, R. Martinez, G. P. Vlasuk, et al. 2009. A synthetic farnesoid X receptor (FXR) agonist promotes cholesterol lowering in models of dyslipidemia. Am. J. Physiol. Gastrointest. Liver Physiol. 296: G543-G552.
31. Genin, M. J., A. B. Bueno, F. J. Agejas, P. R. Manninen, W. P. Bocchinfuso, C. Montrose-Rafizadeh, E. A. Cannady, T. M. Jones, J. R. Stille, E. Raddad, et al. 2015. Discovery of 6-(4-{[5-cyclopropyl- 3-(2, 6-dichlorophenyl)isoxazol-4-yl]methoxy}piperidin-1-yl)- 1-methyl-1H-indole-3-carboxylic acid: a novel FXR agonist for the treatment of dyslipidemia. J. Med. Chem. 58: 9768-9772.
32. Rosenson, R. S., H. B. Jr. Brewer, B. J. Ansell, P. Barter, M. J. Chapman, J. W. Heinecke, A. Kontush, A. Tall, and N. R. Webb. 2016. Dysfunctional HDL and atherosclerotic cardiovascular disease. Nat. Rev. Cardiol. 13: 48-60.
33. Hubbert, M. L., Y. Zhang, F. Y. Lee, and P. A. Edwards. 2007. Regulation of hepatic Insig-2 by the farnesoid X receptor. Mol. Endocrinol. 21: 1359-1369.
34. Trigatti, B., A. Rigotti, and M. Krieger. 2000. The role of the highdensity lipoprotein receptor SR-BI in cholesterol metabolism. Curr. Opin. Lipidol. 11: 123-131.
35. Zhang, Y., L. Yin, J. Anderson, H. Ma, F. J. Gonzalez, T. M. Willson, and P. A. Edwards. 2010. Identification of novel pathways that control farnesoid X receptor-mediated hypocholesterolemia. J. Biol. Chem. 285: 3035-3043.
36. Horton, J. D., N. A. Shah, J. A. Warrington, N. N. Anderson, S. W. Park, M. S. Brown, and J. L. Goldstein. 2003. Combined analysis of oligonucleotide microarray data from transgenic and knockout mice identifies direct SREBP target genes. Proc. Natl. Acad. Sci. USA. 100: 12027-12032.
37. Horton, J. D., J. C. Cohen, and H. H. Hobbs. 2007. Molecular biology of PCSK9: its role in LDL metabolism. Trends Biochem. Sci. 32: 71-77.
38. Ma, A. Z., Z. Y. Song, and Q. Zhang. 2014. Cholesterol efflux is LXR alpha isoform-dependent in human macrophages. BMC Cardiovasc. Disord. 14: 80.
39. Dong, B., C. F. Kan, A. B. Singh, and J. Liu. 2013. High-fructose diet downregulates long-chain acyl-CoA synthetase 3 expression in liver of hamsters via impairing LXR/RXR signaling pathway. J. Lipid Res. 54: 1241-1254.
40. Srivastava, R. A., and S. He. 2010. Anti-hyperlipidemic and insulin sensitizing activities of fenofibrate reduces aortic lipid deposition in hyperlipidemic Golden Syrian hamster. Mol. Cell. Biochem. 345: 197-206.
41. Srivastava, R. A. 2011. Evaluation of anti-atherosclerotic activities of PPAR-alpha, PPAR-gamma, and LXR agonists in hyperlipidemic atherosclerosis-susceptible F(1)B hamsters. Atherosclerosis. 214: 86-93.
42. Dong, B., M. Wu, A. Cao, H. Li, and J. Liu. 2011. Suppression of Idol expression is an additional mechanism underlying statininduced up-regulation of hepatic LDL receptor expression. Int. J. Mol. Med. 27: 103-110.
43. Wiersma, H., A. Gatti, N. Nijstad, R. P. Oude Elferink, F. Kuipers, and U. J. Tietge. 2009. Scavenger receptor class B type I mediates biliary cholesterol secretion independent of ATP-binding cassette transporter g5/g8 in mice. Hepatology. 50: 1263-1272.
44. Meyer, J. M., G. A. Graf, and D. R. Van der Westhuyzen. 2013. New developments in selective cholesteryl ester uptake. Curr. Opin. Lipidol. 24: 386-392.
45. Castro-Torres, I. G., R. de Jesús Cardenas-Vazquez, C. Velazquez- Gonzalez, R. Ventura-Martinez, M. De la O-Arciniega, E. B. Naranjo- Rodriguez, and M. Martinez-Vazquez. 2015. Future therapeutic targets for the treatment and prevention of cholesterol gallstones. Eur. J. Pharmacol. 765: 366-374.
46. Nijstad, N., T. Gautier, F. Briand, D. J. Rader, and U. J. Tietge. 2011. Biliary sterol secretion is required for functional in vivo reverse cholesterol transport in mice. Gastroenterology. 140: 1043-1051.
47. Li, G., A. M. Thomas, J. A. Williams, B. Kong, J. Liu, Y. Inaba, W. Xie, and G. L. Guo. 2012. Farnesoid X receptor induces murine scavenger receptor Class B type I via intron binding. PLoS One. 7: e35895.
48. Chao, F., W. Gong, Y. Zheng, Y. Li, G. Huang, M. Gao, J. Li, R. Kuruba, X. Gao, S. Li, et al. 2010. Upregulation of scavenger receptor class B type I expression by activation of FXR in hepatocyte. Atherosclerosis. 213: 443-448.
49. Yashiro, T., Y. Yokoi, M. Shimizu, J. Inoue, and R. Sato. 2011. Chenodeoxycholic acid stabilization of LDL receptor mRNA depends on 3'-untranslated region and AU-rich element-binding protein. Biochem. Biophys. Res. Commun. 409: 155-159.
50. Langhi, C., M. C. Le, S. Kourimate, S. Caron, B. Staels, M. Krempf, P. Costet, and B. Cariou. 2008. Activation of the farnesoid X receptor represses PCSK9 expression in human hepatocytes. FEBS Lett. 582: 949-955.
51. Ueda, Y., L. Royer, E. Gong, J. Zhang, P. N. Cooper, O. Francone, and E. M. Rubin. 1999. Lower plasma levels and accelerated clearance of high density lipoprotein (HDL) and non-HDL cholesterol in scavenger receptor class B type I transgenic mice. J. Biol. Chem. 274: 7165-7171.